Suppression of RUNX1/ETO oncogenic activity by a small molecule inhibitor of tetramerization

Schanda J. et al.

RUNX1/ETO, the product of the t(8;21) chromosomal translocation, is required for the onset and maintenance of one of the most common forms of acute myeloid leukemia (AML). RUNX1/ETO has a modular structure and, besides the DN A-binding domain (Runt), contains four evolutionary conserved functional domains named nervy homology regions 1-4 (NHR1 to N HR4). The NHR domains serve as docking sites for a variety of different proteins and in addition the N HR2 domain mediates tetramerization through hydrophobic and ionic /polar interactions . Tetramerization is essential for RUNX1/ETO oncogenic activity. Destabilization of the RUNX1/ETO high molecular weight complex abrogates RUNX1/ETO oncogenic activity. Using a structure-based virtual screening, we identified several small molecule inhibitors mimicking the tetramerization hot spot within the NHR2 domain of RUNX1/ETO. One of these compounds, 7.44, was of particular interest as it showed biological activity in vitro and in vivo.


Share this article

February, 2017


Products used in this publication

  • ChIP kit icon
    iDeal ChIP-seq kit for Transcription Factors
  • ChIP-seq Grade
    AML1-ETO Antibody - ChIP-seq Grade
  • Mouse IgG
    Rabbit IgG


  • IMB Conference on "Epigenetics of Ageing - Responses to Adversity across Scales" 2022
    Rheinland-Pfalz, Germany
    Jun 28-Jul 1, 2022
  • CNET 2022
    Gif-Sur-Yvette, France
    Jul 4-Jul 6, 2022



The European Regional Development Fund and Wallonia are investing in your future.

Extension of industrial buildings and new laboratories.

       Site map   |   Contact us   |   Conditions of sales   |   Conditions of purchase   |   Privacy policy   |   Diagenode Diagnostics